Menu
Innovation Observatory > Reports > Drugs > Pembrolizumab (KEYTRUDA®) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line

< Back

Pembrolizumab (KEYTRUDA®) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line

Drugs

Cancer and Palliative Care

July 2017


Pembrolizumab is an immuno-oncology drug administered intravenously that stimulates the body’s immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-L1 on the surface of certain immune cells called T-cells. Blocking the PD-L1 protein triggers the T-cells to find and kill cancer cells. Pembrolizumab is already approved for use in other types of cancers. If licensed in the UK, pembrolizumab in combination with chemotherapy would provide a new treatment option for lung cancer patients who currently have a poor life expectancy and few therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Pembrolizumab in combination for 1L metastatic squamous NSCLC



Load More Related Posts
Get Alerts